Key Takeaways United Therapeutics' Q3 EPS rose 12% to $7.16, which topped expectations but revenues missed.Overall Tyvaso sales climbed 10% year over year, led by 22% growth in Tyvaso DPI.TETON-2 study showed Tyvaso improved lung function in IPF patients, supporting future growth.United Therapeutics (UTHR) reported third-quarter 2025 earnings of $7.16 per share, which beat the Zacks Consensus Estimate of $6.89. Earnings rose 12% year over year on the back of higher product sales.United Therapeutics markets ...

United Therapeutics (NasdaqGS:UTHR) Q3 2025 Earnings Call October 29, 2025 09:00 AM ET Speaker2Good morning everyone and welcome to the United Therapeutics Corporation Third Quarter 2025 Corporate Update. My name is Jamie and I will be your conference operator today. All participants on the call portion of this webcast will be in a listen-only mode until the question and answer portion of this earnings call. If you'd like to ask a question during that time, please press STAR and the number one on your telep ...